3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Phase 2
1
Phase 1/2
1
Status
Recruiting
3
Completed
2
Active not recruiting
1
Sponsor Class
INDUSTRY
3
Study Type
Interventional
3
Sponsor
Cancer Type
Thoracic
1
Gynecologic
1
Gastrointestinal
1
Conditions
Parkinson Disease 4, Autosomal Dominant Lewy Body
2
Ovarian Neoplasms
1
Lung Neoplasms
1
Fallopian Tube Neoplasms
1
Esophageal Squamous Cell Carcinoma
1
Esophageal Neoplasms
1
Interventions
pembrolizumab
241
Carboplatin
167
Injections
138
Paclitaxel
119
Gemcitabine
116
Bevacizumab
112
Cisplatin
105
Docetaxel
82
Cyclophosphamide
78
Pemetrexed
76
Capecitabine
69
Fluorouracil
67
Oxaliplatin
65
Fulvestrant
57
fludarabine
55
Nivolumab
55
Leucovorin
52
Cetuximab
52
130-nm albumin-bound paclitaxel
47
Dexamethasone
46
Rituximab
41
atezolizumab
37
venetoclax
35
Drug Therapy
35
toripalimab
34
enzalutamide
34
Irinotecan
34
durvalumab
32
Prednisone
32
Letrozole
32
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
3 trials
Recent
Start date
Enrollment
Recruiting
×
INDUSTRY
×
Histamine Antagonists
×
Clear all
NCT06788912
2026-06-01
MK-3475-01E
Merck Sharp & Dohme LLC
Phase 2
Recruiting
60 enrolled
NCT06824467
2026-05-29
TroFuse-022
Merck Sharp & Dohme LLC
Phase 3
Recruiting
770 enrolled
NCT05319730
2026-05-26
MK-3475-06B
Merck Sharp & Dohme LLC
Phase 1/2
Recruiting
230 enrolled